Now showing items 1291-1310 of 3378

    • Genome-wide homozygosity signature and risk of Hodgkin lymphoma. 

      Sud, A; Cooke, R; Swerdlow, AJ; Houlston, RS (2015-09-22)
      Recent studies have reported that regions of homozygosity (ROH) in the genome are detectable in outbred populations and can be associated with an increased risk of malignancy. To examine whether homozygosity is associated ...
    • Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses. 

      Christensen, GB; Baffoe-Bonnie, AB; George, A; Powell, I; Bailey-Wilson, JE; Carpten, JD; Giles, GG; Hopper, JL; Severi, G; English, DR; Foulkes, WD; Maehle, L; Moller, P; Eeles, R; Easton, D; Badzioch, MD; Whittemore, AS; Oakley-Girvan, I; Hsieh, C-L; Dimitrov, L; Xu, J; Stanford, JL; Johanneson, B; Deutsch, K; McIntosh, L; Ostrander, EA; Wiley, KE; Isaacs, SD; Walsh, PC; Isaacs, WB; Thibodeau, SN; McDonnell, SK; Hebbring, S; Schaid, DJ; Lange, EM; Cooney, KA; Tammela, TLJ; Schleutker, J; Paiss, T; Maier, C; Grönberg, H; Wiklund, F; Emanuelsson, M; Farnham, JM; Cannon-Albright, LA; Camp, NJ; International Consortium for Prostate Cancer Genetics (2010-05)
      BACKGROUND:Prostate cancer (PC) is generally believed to have a strong inherited component, but the search for susceptibility genes has been hindered by the effects of genetic heterogeneity. The recently developed sumLINK ...
    • Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. 

      Kar, SP; Beesley, J; Amin Al Olama, A; Michailidou, K; Tyrer, J; Kote-Jarai, Z; Lawrenson, K; Lindstrom, S; Ramus, SJ; Thompson, DJ; ABCTB Investigators; Kibel, AS; Dansonka-Mieszkowska, A; Michael, A; Dieffenbach, AK; Gentry-Maharaj, A; Whittemore, AS; Wolk, A; Monteiro, A; Peixoto, A; Kierzek, A; Cox, A; Rudolph, A; Gonzalez-Neira, A; Wu, AH; Lindblom, A; Swerdlow, A; AOCS Study Group & Australian Cancer Study (Ovarian Cancer); APCB BioResource; Ziogas, A; Ekici, AB; Burwinkel, B; Karlan, BY; Nordestgaard, BG; Blomqvist, C; Phelan, C; McLean, C; Pearce, CL; Vachon, C; Cybulski, C; Slavov, C; Stegmaier, C; Maier, C; Ambrosone, CB; Høgdall, CK; Teerlink, CC; Kang, D; Tessier, DC; Schaid, DJ; Stram, DO; Cramer, DW; Neal, DE; Eccles, D; Flesch-Janys, D; Edwards, DRV; Wokozorczyk, D; Levine, DA; Yannoukakos, D; Sawyer, EJ; Bandera, EV; Poole, EM; Goode, EL; Khusnutdinova, E; Høgdall, E; Song, F; Bruinsma, F; Heitz, F; Modugno, F; Hamdy, FC; Wiklund, F; Giles, GG; Olsson, H; Wildiers, H; Ulmer, H-U; Pandha, H; Risch, HA; Darabi, H; Salvesen, HB; Nevanlinna, H; Gronberg, H; Brenner, H; Brauch, H; Anton-Culver, H; Song, H; Lim, H-Y; McNeish, I; Campbell, I; Vergote, I; Gronwald, J; Lubiński, J; Stanford, JL; Benítez, J; Doherty, JA; Permuth, JB; Chang-Claude, J; Donovan, JL; Dennis, J; Schildkraut, JM; Schleutker, J; Hopper, JL; Kupryjanczyk, J; Park, JY; Figueroa, J; Clements, JA; Knight, JA; Peto, J; Cunningham, JM; Pow-Sang, J; Batra, J; Czene, K; Lu, KH; Herkommer, K; Khaw, K-T; kConFab Investigators; Matsuo, K; Muir, K; Offitt, K; Chen, K; Moysich, KB; Aittomäki, K; Odunsi, K; Kiemeney, LA; Massuger, LFAG; Fitzgerald, LM; Cook, LS; Cannon-Albright, L; Hooning, MJ; Pike, MC; Bolla, MK; Luedeke, M; Teixeira, MR; Goodman, MT; Schmidt, MK; Riggan, M; Aly, M; Rossing, MA; Beckmann, MW; Moisse, M; Sanderson, M; Southey, MC; Jones, M; Lush, M; Hildebrandt, MAT; Hou, M-F; Schoemaker, MJ; Garcia-Closas, M; Bogdanova, N; Rahman, N; NBCS Investigators; Le, ND; Orr, N; Wentzensen, N; Pashayan, N; Peterlongo, P; Guénel, P; Brennan, P; Paulo, P; Webb, PM; Broberg, P; Fasching, PA; Devilee, P; Wang, Q; Cai, Q; Li, Q; Kaneva, R; Butzow, R; Kopperud, RK; Schmutzler, RK; Stephenson, RA; MacInnis, RJ; Hoover, RN; Winqvist, R; Ness, R; Milne, RL; Travis, RC; Benlloch, S; Olson, SH; McDonnell, SK; Tworoger, SS; Maia, S; Berndt, S; Lee, SC; Teo, S-H; Thibodeau, SN; Bojesen, SE; Gapstur, SM; Kjær, SK; Pejovic, T; Tammela, TLJ; GENICA Network; PRACTICAL consortium; Dörk, T; Brüning, T; Wahlfors, T; Key, TJ; Edwards, TL; Menon, U; Hamann, U; Mitev, V; Kosma, V-M; Setiawan, VW; Kristensen, V; Arndt, V; Vogel, W; Zheng, W; Sieh, W; Blot, WJ; Kluzniak, W; Shu, X-O; Gao, Y-T; Schumacher, F; Freedman, ML; Berchuck, A; Dunning, AM; Simard, J; Haiman, CA; Spurdle, A; Sellers, TA; Hunter, DJ; Henderson, BE; Kraft, P; Chanock, SJ; Couch, FJ; Hall, P; Gayther, SA; Easton, DF; Chenevix-Trench, G; Eeles, R; Pharoah, PDP; Lambrechts, D (2016-09)
      Breast, ovarian, and prostate cancers are hormone-related and may have a shared genetic basis, but this has not been investigated systematically by genome-wide association (GWA) studies. Meta-analyses combining the largest ...
    • A genome-wide screen identifies the evolutionarily conserved KEOPS complex as a telomere regulator 

      Guillard, Sandrine (2006)
      A genome-wide screen identifies the evolutionarily conserved KEOPS complex as a telomere regulator Telomere capping is the essential function of telomeres. To identify new genes involved in telomere capping, we carried out ...
    • Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). 

      Condorelli, R; Mosele, F; Verret, B; Bachelot, T; Bedard, PL; Cortes, J; Hyman, DM; Juric, D; Krop, I; Bieche, I; Saura, C; Sotiriou, C; Cardoso, F; Loibl, S; Andre, F; Turner, NC (2019-03)
      Better knowledge of the tumor genomic landscapes has helped to develop more effective targeted drugs. However, there is no tool to interpret targetability of genomic alterations assessed by next-generation sequencing in ...
    • Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations 

      Weigelt, B; Reis-Filho, JS; Swanton, C (OXFORD UNIV PRESS, 2012-09)
      Despite improvements in adjuvant chemotherapy regimens in breast cancer; personalised use of specific cytotoxic regimens remains a clinical challenge. Defining the correct therapeutic strategy for individual patients with ...
    • Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. 

      Zafeiriou, Z; Bianchini, D; Chandler, R; Rescigno, P; Yuan, W; Carreira, S; Barrero, M; Petremolo, A; Miranda, S; Riisnaes, R; Rodrigues, DN; Gurel, B; Sumanasuriya, S; Paschalis, A; Sharp, A; Mateo, J; Tunariu, N; Chinnaiyan, AM; Pritchard, CC; Kelly, K; de Bono, JS (2019-01)
      Platinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, ...
    • Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. 

      Woolston, A; Khan, K; Spain, G; Barber, LJ; Griffiths, B; Gonzalez-Exposito, R; Hornsteiner, L; Punta, M; Patil, Y; Newey, A; Mansukhani, S; Davies, MN; Furness, A; Sclafani, F; Peckitt, C; Jiménez, M; Kouvelakis, K; Ranftl, R; Begum, R; Rana, I; Thomas, J; Bryant, A; Quezada, S; Wotherspoon, A; Khan, N; Fotiadis, N; Marafioti, T; Powles, T; Lise, S; Calvo, F; Guettler, S; von Loga, K; Rao, S; Watkins, D; Starling, N; Chau, I; Sadanandam, A; Cunningham, D; Gerlinger, M (2019-07)
      Despite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the cetuximab resistance landscape in 35 RAS ...
    • A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. 

      Scott, RA; Freitag, DF; Li, L; Chu, AY; Surendran, P; Young, R; Grarup, N; Stancáková, A; Chen, Y; Varga, TV; Yaghootkar, H; Luan, J; Zhao, JH; Willems, SM; Wessel, J; Wang, S; Maruthur, N; Michailidou, K; Pirie, A; van der Lee, SJ; Gillson, C; Al Olama, AA; Amouyel, P; Arriola, L; Arveiler, D; Aviles-Olmos, I; Balkau, B; Barricarte, A; Barroso, I; Garcia, SB; Bis, JC; Blankenberg, S; Boehnke, M; Boeing, H; Boerwinkle, E; Borecki, IB; Bork-Jensen, J; Bowden, S; Caldas, C; Caslake, M; CVD50 consortium; Cupples, LA; Cruchaga, C; Czajkowski, J; den Hoed, M; Dunn, JA; Earl, HM; Ehret, GB; Ferrannini, E; Ferrieres, J; Foltynie, T; Ford, I; Forouhi, NG; Gianfagna, F; Gonzalez, C; Grioni, S; Hiller, L; Jansson, J-H; Jørgensen, ME; Jukema, JW; Kaaks, R; Kee, F; Kerrison, ND; Key, TJ; Kontto, J; Kote-Jarai, Z; Kraja, AT; Kuulasmaa, K; Kuusisto, J; Linneberg, A; Liu, C; Marenne, G; Mohlke, KL; Morris, AP; Muir, K; Müller-Nurasyid, M; Munroe, PB; Navarro, C; Nielsen, SF; Nilsson, PM; Nordestgaard, BG; Packard, CJ; Palli, D; Panico, S; Peloso, GM; Perola, M; Peters, A; Poole, CJ; Quirós, JR; Rolandsson, O; Sacerdote, C; Salomaa, V; Sánchez, M-J; Sattar, N; Sharp, SJ; Sims, R; Slimani, N; Smith, JA; Thompson, DJ; Trompet, S; Tumino, R; van der A, DL; van der Schouw, YT; Virtamo, J; Walker, M; Walter, K; GERAD_EC Consortium; Neurology Working Group of the Cohorts for Heart; Aging Research in Genomic Epidemiology (CHARGE); Alzheimer’s Disease Genetics Consortium; Pancreatic Cancer Cohort Consortium; European Prospective Investigation into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD); EPIC-InterAct; Abraham, JE; Amundadottir, LT; Aponte, JL; Butterworth, AS; Dupuis, J; Easton, DF; Eeles, RA; Erdmann, J; Franks, PW; Frayling, TM; Hansen, T; Howson, JMM; Jørgensen, T; Kooner, J; Laakso, M; Langenberg, C; McCarthy, MI; Pankow, JS; Pedersen, O; Riboli, E; Rotter, JI; Saleheen, D; Samani, NJ; Schunkert, H; Vollenweider, P; O'Rahilly, S; CHARGE consortium; CHD Exome+ Consortium; CARDIOGRAM Exome Consortium; Deloukas, P; Danesh, J; Goodarzi, MO; Kathiresan, S; Meigs, JB; Ehm, MG; Wareham, NJ; Waterworth, DM (2016-06)
      Regulatory authorities have indicated that new drugs to treat type 2 diabetes (T2D) should not be associated with an unacceptable increase in cardiovascular risk. Human genetics may be able to guide development of antidiabetic ...
    • Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients 

      Stratton, M (2010-06)
      Distinct molecular subtypes of breast carcinomas have been identified, but translation into clinical use has been limited. We have developed two platform-independent algorithms to explore genomic architectural distortion ...
    • A genomic atlas of human adrenal and gonad development. 

      Del Valle, I; Buonocore, F; Duncan, AJ; Lin, L; Barenco, M; Parnaik, R; Shah, S; Hubank, M; Gerrelli, D; Achermann, JC (2017-04-07)
      In humans, the adrenal glands and gonads undergo distinct biological events between 6-10 weeks post conception (wpc), such as testis determination, the onset of steroidogenesis and primordial germ cell development. However, ...
    • Genomic Classification and Prognosis in Acute Myeloid Leukemia. 

      Papaemmanuil, E; Gerstung, M; Bullinger, L; Gaidzik, VI; Paschka, P; Roberts, ND; Potter, NE; Heuser, M; Thol, F; Bolli, N; Gundem, G; Van Loo, P; Martincorena, I; Ganly, P; Mudie, L; McLaren, S; O'Meara, S; Raine, K; Jones, DR; Teague, JW; Butler, AP; Greaves, MF; Ganser, A; Döhner, K; Schlenk, RF; Döhner, H; Campbell, PJ (2016-06)
      Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology of AML and informs clinical ...
    • Genomic correlates of clinical outcome in advanced prostate cancer. 

      Abida, W; Cyrta, J; Heller, G; Prandi, D; Armenia, J; Coleman, I; Cieslik, M; Benelli, M; Robinson, D; Van Allen, EM; Sboner, A; Fedrizzi, T; Mosquera, JM; Robinson, BD; De Sarkar, N; Kunju, LP; Tomlins, S; Wu, YM; Nava Rodrigues, D; Loda, M; Gopalan, A; Reuter, VE; Pritchard, CC; Mateo, J; Bianchini, D; Miranda, S; Carreira, S; Rescigno, P; Filipenko, J; Vinson, J; Montgomery, RB; Beltran, H; Heath, EI; Scher, HI; Kantoff, PW; Taplin, M-E; Schultz, N; deBono, JS; Demichelis, F; Nelson, PS; Rubin, MA; Chinnaiyan, AM; Sawyers, CL (2019-06)
      Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of this heterogeneity on clinical outcome. Here, ...
    • Genomic gain and over expression of CCL2 correlate with vascular invasion in stage I non-seminomatous testicular germ-cell tumours. 

      Gilbert, DC; Chandler, I; Summersgill, B; McIntyre, A; Missiaglia, E; Goddard, NC; Huddart, RA; Shipley, J (2011-08)
      Testicular germ-cell tumours (TGCT) are the most frequent solid tumour to affect young Caucasian adult males and have increased in incidence over recent decades. In clinical stage I non-seminomas, (NSGCT) histological ...
    • Genomic instability and the selection of treatments for cancer. 

      Martin, SA; Hewish, M; Lord, CJ; Ashworth, A (2010-01)
      A critical link exists between DNA mutation and chromosomal rearrangements (genomic instability) and cancer development. This genomic instability can manifest itself as small changes at the nucleotide level or as gross ...
    • Genomic instability and TP53 genomic alterations associate with poor anti-proliferative response and intrinsic resistance to aromatase inhibitor treatment 

      Schuster, E; Gellert, P; Segal, C; Lopez-Knowles, E; Buus, R; Cheang, M; Morden, J; Robertson, J; Bliss, J; Smith, I; Dowsett, M
    • The genomic landscape of plasma cells in systemic light chain amyloidosis. 

      Boyle, EM; Ashby, C; Wardell, CP; Rowczenio, D; Sachchithanantham, S; Wang, Y; Johnson, SK; Bauer, MA; Weinhold, N; Kaiser, MF; Johnson, DC; Jones, JR; Pawlyn, C; Proszek, P; Schinke, C; Facon, T; Dumontet, C; Davies, FE; Morgan, GJ; Walker, BA; Wechalekar, AD (2018-12)
    • The genomic landscape of testicular germ cell tumours: from susceptibility to treatment. 

      Litchfield, K; Levy, M; Huddart, RA; Shipley, J; Turnbull, C (2016-07)
      The genomic landscape of testicular germ cell tumour (TGCT) can be summarized using four overarching hypotheses. Firstly, TGCT risk is dominated by inherited genetic factors, which determine nearly half of all disease risk ...
    • Genomic loss of heterozygosity and survival in the REAL3 trial. 

      Smyth, EC; Cafferkey, C; Loehr, A; Waddell, T; Begum, R; Peckitt, C; Harding, TC; Nguyen, M; Okines, AF; Raponi, M; Rao, S; Watkins, D; Starling, N; Middleton, GW; Wadsley, J; Mansoor, W; Crosby, T; Wotherspoon, A; Chau, I; Cunningham, D (2018-11-30)
      Background:Homologous recombination deficiency (HRD) measured using a genomic signature for loss of heterozygosity (LOH) predicts benefit from rucaparib in ovarian cancer. We hypothesized that some oesophagogastric cancers ...
    • Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC). 

      Barry, GS; Cheang, MC; Chang, HL; Kennecke, HF (2016-04)
      A prospective study was conducted to identify biomarkers associated with resistance to panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Patients with previously treated, codon 12/13 KRAS wt, ...